Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Opsens to Present at the Lytham Partners Winter 2021 Investor Conference: Presentation at 11 Am (ET), Monday December 13, 2021

QUEBEC, Dec. 7, 2021/CNW Telbec/ -OpSens inc.(«OpSens» or the «Company») (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, announced today that it will be participating in the Lytham Partners Winter 2021 Investor Conference taking place from December 13-16, 2021. During the event, the Company will be participating in a webcasted Fireside Chat, discussing its vision for 2022 and conducting 1x1 virtual investor meetings.

OpSens inc. Logo (CNW Group/OPSENS Inc.)

The webcasted Fireside Chat will be available for viewingon Monday, December 13, at 11 AM ET on OpSens' website at www.opsens.com or https://wsw.com/webcast/lytham3/ops.to/2315750. The webcast will be archived and available for replay following the live event.

Management will also be participating in virtual one-on-one meetings throughout the event, which runs from December 13-16, 2021. To arrange a meeting, please contact a Lytham Partners representative at 1x1@lythampartners.com or register at www.lythampartners.com/winter2021invreg.

About OpSens Inc. (www.OpSens.com or www.OpSensmedical.com)

OpSens focuses mainly in interventional cardiology. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of over 150,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada.

OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.

Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, and achievements of OpSens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

SOURCE OPSENS Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2021/07/c8985.html

Tags:


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today